Threshold dose of factor IX expression in non-human primates following IV administration of AAV8 vectors

被引：0
|
作者：
Mizukami, Hiroaki [1 ]
Mimuro, Jun [2 ]
Tsukahara, Tomonori [1 ]
Urabe, Masashi [1 ]
Kume, Akihiro [1 ]
Ohmori, Tsukasa [2 ]
Madoiwa, Seiji [2 ]
Sakata, Yoichi [2 ]
Ozawa, Keiya [1 ]
机构：
[1] Jichi Med Univ, Ctr Mol Med, Div Genet Therapeut, Shimotsuke, Japan
[2] Jichi Med Univ, Ctr Mol Med, Div Cell & Mol Med, Shimotsuke, Japan
来源：
HUMAN GENE THERAPY | 2012年 / 23卷 / 10期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：A77 / A78
页数：2
相关论文
共 50 条
  • [31] Systemic and local immune responses to intraocular AAV vector administration in non-human primates
    Ail, Divya
    Ren, Duohao
    Brazhnikova, Elena
    Nouvel-Jaillard, Celine
    Bertin, Stephane
    Mirashrafi, Seyed Bagher
    Fisson, Sylvain
    Dalkara, Deniz
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2022, 24 : 306 - 316
  • [32] Subfoveal Injections in Non-Human Primates: Safety and Efficacy Following Administration of a Photoreceptor-Targeted AAV5
    Boyd, Ryan F.
    Bartoe, Joshua T.
    Vihtelic, Thomas S.
    Boye, Sanford L.
    Boye, Shannon Elizabeth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [33] Dose-dependent inflammation signatures following Ixo-vec administration in non-human primates
    Ramos, J. N.
    Nieves, J. D.
    Tarazkar, M.
    Belbellaa, B.
    Grishanin, R.
    Riley, B. E.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A14 - A14
  • [34] AAV204, a Novel AAV Capsid, Demonstrates Superior Macular Transduction Following Para-Retinal Administration in Non-human Primates
    Kevany, Brian
    Kerns, Scott
    Padegimas, Linas
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [35] Use of Evader-AAV8 for repeat dosing in mice and non-human primates
    Rosario, A.
    Paolilli, K.
    Levinson, M.
    Diaz, C. Ceballos
    Mishra, A.
    Shenoy, K.
    Miller, M.
    Maguire, C. A.
    Fitzpatrick, P. A.
    Winslow, G.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A50 - A50
  • [36] EFFECTIVE TRANSGENE EXPRESSION IN NON-HUMAN PRIMATE MUSCLE WITH AAV TYPE 9 VECTORS FOLLOWING IMMUNE SUPPRESSION
    Ishii, Akiko
    Okada, Hironori
    Hayashita-Kinoh, Hiromi
    Shin, Jin-Hong
    Okada, Takashi
    Takeda, Shin'ichi
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 250 - 251
  • [37] Quality control and quality assurance of novel AAV vectors for gene transfer studies in non-human primates
    Hammill, DM
    Calcedo, R
    Qin, QY
    Sanmiguel, J
    Gallery, L
    Gao, GP
    Wilson, JM
    MOLECULAR THERAPY, 2003, 7 (05) : S346 - S347
  • [38] Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates
    Liu, Ying Poi
    Lubelski, Jacek
    Ehlert, Erich
    Gielen, Sander
    Miranda, Paula
    de Haan, Martin
    Nijmeijer, Bart
    Petry, Harald
    BLOOD, 2017, 130
  • [39] Novel Surgical Method for Intravitreal AAV Administration Overcomes Transduction Barriers in Non-Human Primates
    Comander, Jason
    Carvalho, Livia
    Wassmer, Sarah
    Xiao, Ru
    Plovie, Eva
    Langsdorf, Aliete
    Lim, Lawrence
    Er, Brian Hafl
    Wu, David M.
    Eliott, Dean
    Kim, Leo A.
    Vandenberghe, Luk H.
    MOLECULAR THERAPY, 2016, 24 : S13 - S14
  • [40] Immune-driven gene expression loss following intramuscular AAV delivery to non-human primates is only transient
    Journou, Malo
    Devaux, Marie
    Jaulin, Nicolas
    Pichard, Virginie
    Segovia, Mercedes
    Moreau, Aurelie
    Le Duff, Johanne
    Cuturi, Maria Cristina
    Guilbaud, Mickael
    Adjali, Oumeya
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2025, 33 (01)
12345